Drugs / AUR108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05984147 | Oct 2023 → Aug 2027 expected | — | Aurigene Discovery Technologies Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05984147 ↗ |
| Route | Oral | “oral AUR108 will be evaluated” NCT05984147 ↗ |